Review article · 2023 · Open access

Artificial Intelligence for Drug Discovery: Are We There Yet?

Catrin Hasselgren, Tudor Ionel Oprea

The Annual Review of Pharmacology and Toxicology, 64(1), 527–550 · Published 22 September 2023 · DOI 10.1146/annurev-pharmtox-040323-040828

Open PDFView at the publisherCite this paper

In brief

“Artificial Intelligence for Drug Discovery: Are We There Yet?” is a 2023 review article by Catrin Hasselgren and Tudor Ionel Oprea, published in The Annual Review of Pharmacology and Toxicology. OpenAlex counts 311 citations as of 22 November 2026, which puts it in the top 3% of works published in 2023 by citations. It is open access under a public domain licence: the full text is free to read at The Annual Review of Pharmacology and Toxicology.

Citations
311
Most cited in
2025 (137)
Field-weighted impact
4.55
References
176
Authors
2

Abstract

Drug discovery is adapting to novel technologies such as data science, informatics, and artificial intelligence (AI) to accelerate effective treatment development while reducing costs and animal experiments. AI is transforming drug discovery, as indicated by increasing interest from investors, industrial and academic scientists, and legislators. Successful drug discovery requires optimizing properties related to pharmacodynamics, pharmacokinetics, and clinical outcomes. This review discusses the use of AI in the three pillars of drug discovery: diseases, targets, and therapeutic modalities, with a focus on small-molecule drugs. AI technologies, such as generative chemistry, machine learning, and multiproperty optimization, have enabled several compounds to enter clinical trials. The scientific community must carefully vet known information to address the reproducibility crisis. The full potential of AI in drug discovery can only be realized with sufficient ground truth and appropriate human intervention at later pipeline stages.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Hasselgren, C., & Oprea, T. I. (2023). Artificial Intelligence for Drug Discovery: Are We There Yet? The Annual Review of Pharmacology and Toxicology, 64(1), 527–550. https://doi.org/10.1146/annurev-pharmtox-040323-040828

MLA 9

Hasselgren, Catrin, and Tudor Ionel Oprea. “Artificial Intelligence for Drug Discovery: Are We There Yet?” The Annual Review of Pharmacology and Toxicology, vol. 64, no. 1, 2023, pp. 527–550. https://doi.org/10.1146/annurev-pharmtox-040323-040828.

Chicago

Hasselgren, Catrin and Tudor Ionel Oprea. 2023. “Artificial Intelligence for Drug Discovery: Are We There Yet?” The Annual Review of Pharmacology and Toxicology 64 (1): 527–550. https://doi.org/10.1146/annurev-pharmtox-040323-040828.

Harvard

Hasselgren, C. and Oprea, T. I. (2023) ‘Artificial Intelligence for Drug Discovery: Are We There Yet?’, The Annual Review of Pharmacology and Toxicology, 64(1), pp. 527–550. doi:10.1146/annurev-pharmtox-040323-040828.

IEEE

C. Hasselgren and T. I. Oprea, “Artificial Intelligence for Drug Discovery: Are We There Yet?,” The Annual Review of Pharmacology and Toxicology, vol. 64, no. 1, pp. 527–550, 2023, doi: 10.1146/annurev-pharmtox-040323-040828.

BibTeX

@article{hasselgren2023artificial,
  title     = {{Artificial Intelligence for Drug Discovery: Are We There Yet?}},
  author    = {Hasselgren, Catrin and Oprea, Tudor Ionel},
  journal   = {The Annual Review of Pharmacology and Toxicology},
  year      = {2023},
  volume    = {64},
  number    = {1},
  pages     = {527--550},
  doi       = {10.1146/annurev-pharmtox-040323-040828},
  url       = {https://doi.org/10.1146/annurev-pharmtox-040323-040828}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202355
20246868
2025137137
2026101101

Its field-weighted citation impact is 4.55: it has been cited 4.55 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods

  • artificial intelligence in drug discovery
  • generative chemistry
  • machine learning
  • small molecule drugs
  • therapeutic target
  • therapeutic modalities
  • replication crisis
  • clinical trial candidates

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Hasselgren, C., & Oprea, T. I. (2023). Artificial Intelligence for Drug Discovery: Are We There Yet? The Annual Review of Pharmacology and Toxicology, 64(1), 527–550. https://doi.org/10.1146/annurev-pharmtox-040323-040828

How many times has this paper been cited?

311 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The Annual Review of Pharmacology and Toxicology: sign in and open the PDF from this page.

Who wrote this paper?

Catrin Hasselgren, Tudor Ionel Oprea.

What is the DOI of this paper?

10.1146/annurev-pharmtox-040323-040828, permanently at https://doi.org/10.1146/annurev-pharmtox-040323-040828. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.